Company profile
Kaleido Biosciences, Inc.
OTC: KLDO · Healthcare · Biotechnology
#867 of 1,422 Healthcare companies by revenue59th-percentile growth
EA Score
——FH —DQ 49GM —SS 34
v0.1 · 25/100 weight · pillars only
↑ filing timeliness, revenue growth (YoY) · ↓ return on equity, disclosure history
Methodology →Revenue TTM
$1.1M
Rev growth YoY (TTM)
+13.2%
Net income (FY)
-$90.3M
Employees
76
as of 2026-08-30
Market cap
$4.3k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.1M$1.1M2021
Net income-$90.3M-$90.3M2021
Operating income-$87.7M-$87.7M2021
Total assets$50.1M$50.1M2021
Liabilities$39.5M$39.5M2021
Equity$10.6M$10.6M2021
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Kaleido Biosciences, Inc.’s revenue?
Kaleido Biosciences, Inc. booked $1.1M in FY2021 revenue, growing 13% year over year — about the middle of the pack among Healthcare companies we track, at a -8178.3% net margin.
Peers · Healthcare
PetVivo Holdings, Inc.38DRenovoRx, Inc.32DBespoke Extracts, Inc.——White River Energy Corp.——Matinas BioPharma Holdings, Inc.32DReflect Scientific, Inc.——Neighbors
Middlesex →Key facts
CEOMark A. Wingertzahn
SectorHealthcare
IndustryBiotechnology
HeadquartersLexington, MA
ExchangeOTC: KLDO
Employees76
IPO date2019-02-28
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.